Hospital
Prime Healthcare Services - Garden Grove LLC
Prime Healthcare Services - Garden Grove LLC was paid $6.67M by Medicaid between Jan 2018 and Dec 2024, across 190 billing codes. Its largest line is 0450, Emergency room services — 8.3% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES - GARDEN GROVE LLC
GARDEN GROVE, CA 92843
GARDEN GROVE, CA 92843
33aNPI1659538858assigned 05/16/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.67M
24GClaims612,766
24DCodes billed190
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#210 of 410
Median peer was paid$6.90M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 108,529 | $901K | |
| 2019 | 106,001 | $1.14M | |
| 2020 | 87,030 | $980K | |
| 2021 | 85,759 | $738K | |
| 2022 | 101,268 | $947K | |
| 2023 | 81,772 | $1.21M | |
| 2024incomplete | 42,407 | $758K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 8.3% | 64,028 | 54,789 | $554K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.2% | 13,825 | 10,898 | $481K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 6.9% | 12,451 | 8,572 | $464K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.9% | 2,823 | 2,277 | $395K |
| Z7502 | 5.3% | 9,376 | 9,198 | $352K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.1% | 7,125 | 5,863 | $274K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.5% | 5,210 | 4,099 | $233K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 5,451 | 4,784 | $226K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.0% | 9,411 | 7,230 | $198K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.8% | 2,622 | 2,185 | $189K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.7% | 16,615 | 13,508 | $180K |
| J3490 | Unclassified drugs | 2.4% | 34,281 | 15,709 | $163K |
178 more codes
| 80053 | Comprehensive metabolic panel | 2.4% | 29,737 | $159K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 4,023 | $154K |
| 87428 | 2.3% | 3,472 | $153K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 10,215 | $149K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 34,851 | $140K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.1% | 9,747 | $138K |
| Z7500 | 1.5% | 2,969 | $101K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 3,141 | $99K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.4% | 16,682 | $94K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 12,237 | $87K |
| 99199 | Unlisted special service, procedure or report | 1.3% | 1,675 | $85K |
| 99285 | Emergency room visit (most serious) | 1.0% | 1,995 | $68K |
| 83690 | <1% | 18,480 | $63K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,133 | $62K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,749 | $61K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,527 | $59K |
| Z7610 | <1% | 5,275 | $57K | |
| 99284 | Emergency room visit (serious) | <1% | 1,841 | $56K |
| 81025 | <1% | 21,125 | $53K | |
| 99283 | Emergency room visit (moderate) | <1% | 4,557 | $52K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,513 | $48K |
| 84484 | <1% | 10,592 | $46K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,701 | $43K |
| 90715 | <1% | 1,800 | $39K | |
| 83880 | <1% | 2,708 | $37K | |
| 0270 | <1% | 41,715 | $35K | |
| 81001 | <1% | 21,864 | $32K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,730 | $31K |
| 59025 | Fetal non-stress test | <1% | 1,694 | $31K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,253 | $31K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,425 | $31K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,356 | $29K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,640 | $28K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,441 | $28K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 661 | $28K |
| 76801 | <1% | 666 | $25K | |
| 87040 | <1% | 5,844 | $24K | |
| 76830 | Ultrasound, transvaginal | <1% | 478 | $20K |
| 94762 | <1% | 808 | $19K | |
| 83605 | <1% | 4,038 | $18K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,326 | $18K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 288 | $17K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,612 | $17K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 569 | $17K |
| 73610 | <1% | 1,143 | $16K | |
| 73630 | <1% | 1,156 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,300 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,607 | $13K |
| 73562 | <1% | 980 | $12K | |
| 73130 | <1% | 883 | $12K | |
| 93971 | <1% | 149 | $11K | |
| 87186 | <1% | 2,768 | $11K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 701 | $11K |
| 85730 | <1% | 3,861 | $11K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 689 | $11K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,432 | $10K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,288 | $10K |
| 84145 | <1% | 991 | $10K | |
| 85610 | <1% | 5,444 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,312 | $9K |
| 73030 | <1% | 727 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 561 | $9K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 49 | $9K |
| 82962 | <1% | 6,672 | $8K | |
| 70486 | <1% | 172 | $8K | |
| 84702 | <1% | 1,496 | $8K | |
| 85379 | <1% | 1,513 | $8K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 290 | $8K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,813 | $7K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,789 | $7K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,415 | $7K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,726 | $6K |
| 72131 | <1% | 103 | $6K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 194 | $6K |
| 83735 | <1% | 1,608 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,363 | $5K |
| 73110 | <1% | 352 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,398 | $4K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 213 | $4K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 542 | $4K |
| 87070 | <1% | 1,735 | $4K | |
| 87088 | <1% | 1,012 | $4K | |
| 86901 | <1% | 2,211 | $3K | |
| 93970 | <1% | 31 | $3K | |
| 86900 | <1% | 2,210 | $3K | |
| 82550 | <1% | 1,152 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 711 | $3K |
| 73080 | <1% | 174 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 284 | $3K |
| 0250 | <1% | 6,066 | $2K | |
| 12001 | <1% | 211 | $2K | |
| 0012A | <1% | 41 | $2K | |
| 29125 | <1% | 488 | $2K | |
| 0001A | <1% | 35 | $1K | |
| 86141 | <1% | 216 | $1K | |
| 82947 | <1% | 360 | $1K | |
| 86850 | <1% | 640 | $988.37 | |
| 0002A | <1% | 24 | $960.00 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 12 | $855.67 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 177 | $836.94 |
| 0011A | <1% | 20 | $800.00 | |
| 74018 | <1% | 108 | $687.23 | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 15 | $603.69 |
| 96376 | <1% | 669 | $600.40 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,835 | $577.59 |
| 0272 | <1% | 3,455 | $577.52 | |
| 88312 | <1% | 91 | $557.90 | |
| 81005 | <1% | 870 | $541.18 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 125 | $540.82 |
| 73090 | <1% | 53 | $536.88 | |
| 71010 | <1% | 54 | $536.04 | |
| 73140 | <1% | 59 | $532.96 | |
| 29515 | <1% | 104 | $523.65 | |
| 76770 | <1% | 12 | $518.70 | |
| 12002 | <1% | 43 | $514.31 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 70 | $505.19 |
| 87184 | <1% | 196 | $487.50 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 107 | $456.23 |
| 72100 | <1% | 29 | $452.50 | |
| J1815 | Injection, insulin, per 5 units | <1% | 91 | $422.30 |
| 73590 | <1% | 42 | $414.03 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 273 | $346.20 |
| 73502 | <1% | 16 | $336.63 | |
| 10060 | <1% | 39 | $315.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 95 | $290.31 |
| 82009 | <1% | 130 | $279.59 | |
| 85027 | <1% | 1,119 | $270.76 | |
| 87077 | <1% | 85 | $265.08 | |
| 80076 | <1% | 82 | $240.06 | |
| 96368 | <1% | 17 | $226.35 | |
| 84439 | <1% | 60 | $215.43 | |
| 87420 | <1% | 149 | $212.32 | |
| 29505 | <1% | 52 | $189.04 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 40 | $177.49 |
| 71020 | <1% | 15 | $174.79 | |
| 12011 | <1% | 26 | $165.60 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 37 | $150.00 |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 37 | $148.82 |
| 87081 | <1% | 25 | $145.06 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 35 | $142.80 |
| 0636 | <1% | 782 | $135.35 | |
| 0762 | <1% | 234 | $116.94 | |
| 82150 | <1% | 39 | $113.55 | |
| 85651 | <1% | 53 | $98.08 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 12 | $87.97 |
| 29130 | <1% | 27 | $79.20 | |
| 87205 | <1% | 21 | $51.60 | |
| 84100 | <1% | 18 | $26.90 | |
| 0710 | <1% | 709 | $26.13 | |
| 36600 | <1% | 14 | $25.20 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 12 | $20.18 |
| A4606 | Oxygen probe for use with oximeter device, replacement | <1% | 28 | $20.05 |
| 85652 | <1% | 12 | $16.14 | |
| 82270 | <1% | 12 | $14.99 | |
| 81003 | <1% | 337 | $11.46 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 17 | $5.89 |
| 0271 | <1% | 366 | $2.39 | |
| 85007 | <1% | 13 | $1.26 | |
| 85008 | <1% | 66 | $0.98 | |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 13 | $0.91 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 262 | $0.01 |
| 0760 | 0% | 611 | $0.00 | |
| 0402 | 0% | 108 | $0.00 | |
| 0360 | 0% | 118 | $0.00 | |
| 0320 | 0% | 91 | $0.00 | |
| 0302 | 0% | 78 | $0.00 | |
| 0351 | 0% | 71 | $0.00 | |
| 0160 | 0% | 18 | $0.00 | |
| 0305 | 0% | 395 | $0.00 | |
| 0370 | 0% | 152 | $0.00 | |
| A4615 | Cannula, nasal | 0% | 47 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 30 | $0.00 |
| 0761 | 0% | 2,390 | $0.00 | |
| 0301 | 0% | 809 | $0.00 | |
| 0324 | 0% | 109 | $0.00 | |
| 0352 | 0% | 74 | $0.00 | |
| 0307 | 0% | 145 | $0.00 | |
| 0306 | 0% | 232 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.